Skip to content
The Nexus
DossierENTITY

Leo Pharma

Coverage of Leo Pharma in the Nexus archive.

Earliest in view: Apr 13 · 13:15 UTCMost recent: Jun 17 · 03:00 UTC
Co-mentioned in this coverage
Recent coverage
  • HEALTHJun 17 · 03:00 UTCPOLITICO EUROPE
    Do we want to lead or lag in life sciences?

    Europe risks losing its leadership in the pharmaceutical sector due to geopolitical challenges and internal indifference, with the United States' Most-Favored-Nation pricing policy and China's rapid advancements in biotechnology and innovation exacerbating the decline. Europe lags behind in clinical trials, R&D spending, and attracting investment compared to the US and China.

  • BUSINESSMay 5 · 07:00 UTCBLOOMBERG
    Leo Pharma Eyes $800 Million Deal Push as IPO Plans Advance

    Leo Pharma is moving forward with its IPO plans and is considering a deal worth $800 million. The company has a pharmaceutical manufacturing plant. Leo Pharma's advancements in IPO plans may lead to significant financial gains.

  • BUSINESSApr 13 · 13:15 UTCBLOOMBERG
    Drugmaker Leo Pharma Is Said to Pick Banks for Copenhagen IPO

    Drugmaker Leo Pharma is preparing for an initial public offering (IPO) on the Copenhagen Stock Exchange. The company is said to be selecting banks to facilitate the IPO process.

Leo Pharma · Dossier · The Nexus